MPLT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MapLight Therapeutics Inc (MPLT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, a bullish technical setup, and upcoming Phase 2 data in Q3, which could act as a significant catalyst. Despite the lack of immediate trading signals and current financial losses, the company's cash position and growth potential in the CNS therapeutics market make it a compelling long-term investment.
The technical indicators for MPLT are bullish. The MACD is positive and contracting, indicating upward momentum. The RSI is neutral at 56.298, showing no signs of overbought or oversold conditions. The moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), and the stock is trading above its pivot point of 28.681, with resistance levels at 32.038 and 34.113.
Strong analyst support with multiple Buy ratings and price targets of $35-$37, indicating significant upside potential.
Upcoming Phase 2 data for ML-007C-MA in schizophrenia in Q3, which could be a major catalyst.
The company's cash reserves of $453.1 million are sufficient to fund operations through 2027, reducing financial risk.
Insider selling by the Chief Discovery Officer, though it represents only 1% of their holdings.
No immediate profitability, with widening net losses and no revenue growth in the latest quarter.
In Q4 2025, MapLight reported no revenue growth and a net loss of $79.5 million. However, EPS improved significantly by 892.51% YoY to -18.56, and the company has a strong cash position of $453.1 million, sufficient to fund operations through 2027.
Analysts are highly bullish on MPLT, with multiple Buy ratings and price targets ranging from $35 to $37. They view the stock as undervalued based on its schizophrenia opportunity alone and anticipate significant growth potential from its lead asset ML-007C-MA.
